| Trial ID: | L1456 |
| Source ID: | NCT01029587
|
| Associated Drug: |
Eculizumab
|
| Title: |
Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01029587/results
|
| Conditions: |
Antiphospholipid Antibody Syndrome|End Stage Renal Disease
|
| Interventions: |
DRUG: Eculizumab
|
| Outcome Measures: |
Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant, 6 months | Secondary: Number of Patients With Kidney Transplant Graft Survival, 6 months|Number of Patients Who Survive, 6 months
|
| Sponsor/Collaborators: |
Sponsor: Johns Hopkins University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
1
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2009-11
|
| Completion Date: |
2010-05-06
|
| Results First Posted: |
2020-10-26
|
| Last Update Posted: |
2020-10-26
|
| Locations: |
Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01029587
|
